Heart failure is a serious manifestation or terminal stage of various heart diseases,with high mortality and rehospitalization rate.Therefore,how to improve patients'prognosis and quality of life etc.has become a research hotspot.As a new hypoglycemics,sodium-glucose cotransporter 2 inhibitor has been proved by many experiments to improve the prognosis of patients with heart failure.This article aims to elaborate it from aspects of mechanism,clinical research and the latest clinical guidelines in order to provide better treatment for patients with heart failure.
维普
万方数据